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4.3 The TRIPS Agreement and Human Rights 
The TRIPS Agreement (or “TRIPS”) was adopted in 1994 following intense pressure 
exerted by the US and other industrialized countries.100 Prior to the adoption of 
TRIPS, the international framework for the regulation and protection of intellectual 
property rights consisted of a few GATT rules and a number of conventions, most of 
which were and still are administered by the World Intellectual Property 
Organisation (WIPO).101 At the national level, patent protection varied between 
countries. While some countries granted patents for pharmaceutical product and 
process inventions, others allowed patent protection only with respect to process 
inventions. Many did not grant any form of protection for inventions in the 
                                               
100 The TRIPS Agreement is contained in Annex 1C to the Marrakesh Agreement Establishing the 
WTO. According to Correa, the developing countries accepted the TRIPS Agreement partly because of 
“the expectation of increased market access for agricultural products and textiles, and … the fear that 
if they did not agree they would be increasingly vulnerable to unilateral arm-twisting by the major 
powers”. See Correa CM Trade Related Aspects of Intellectual Property Rights: A Commentary on the 
TRIPS Agreement (2007) 15. See also Velasquez G and Boulet P Globalization and Access to Drugs: 
Implications of the WTO/TRIPS Agreement, Health and Drugs DAP Series No 7, 2 ed (1999) 40; 
Gervais D The TRIPS Agreement: Drafting History and Analysis (2003) 3-51; Hoekman B and Kostecki 
M The Political Economy of the World Trading System: The WTO and Beyond (2001) 297; Thomas and 
Meyer (fn 8 above) 259. 
101 Gervais (fn 100 above) 5-10. WIPO administers two main international treaties on intellectual 
property: the Paris Convention for the Protection of Industrial Property 1967 and the Berne 
Convention for the Protection of Literary and Artistic Works 1971. 
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pharmaceutical sector.102 Further, the period of patent protection varied 
significantly between countries.  
 In response to the perceived inadequacies of the existing rules concerning the 
absence of detailed rules on the enforcement of intellectual property rights before 
national judicial authorities and the lack of an effective international dispute 
settlement system, the US and the European Community  (now called the European 
Union) argued for the inclusion of intellectual property matters into the Uruguay 
Round trade negotiations.103 Unlike the pre-TRIPS conventions on intellectual 
property rights, the TRIPS Agreement provides for enforcement of such rights. In 
particular, it links the obligations of the TRIPS Agreement with those of the WTO 
Agreement and thus ensures that a violation of the TRIPS Agreement can, in certain 
circumstances, be punished through the use of trade-related sanctions.104 These 
provisions essentially reflect the wishes of the US and other developed countries 
which had contended that the mere guarantee of rights was insufficient and that 
holders of intellectual property rights should be afforded the opportunity to 
effectively exercise them.105 
 The TRIPS Agreement stipulates some general obligations for compliance, by all 
WTO Member States irrespective of their level of development, with certain 
minimum standards of protection of intellectual property, which are in practice the 
standards applied in developed countries.106 However, in recognition of the 
difficulties that some Members might encounter in implementing it, TRIPS provides 
for progressive implementation of its obligations. Thus, developing countries and 
least developed countries (LDCs), were allowed five years and 11 years (with the 
possibility of an extension), respectively,  to implement the obligations contained in 
the Agreement (with the exception of articles 3, 4 and 5). The Doha Declaration 
extends this delay in relation to patents on medicines to 2016 (see below). 
 It is worthy of note that, unlike the other WTO agreements, the TRIPS Agreement 
does not aim to liberalize trade. Rather, its purpose is to establish rules for the 
acquisition of intellectual property and the control over the production and trade of 
the products derived therefrom.107 
(a) Overview of the Main Provisions 
The TRIPS Agreement extends the application to intellectual property rights of three 
GATT principles, namely, national treatment, most-favoured nation treatment 
(MFN) and transparency; stipulates general rules to be met by the procedures for 
the acquisition and maintenance of intellectual property rights; and provides for 
                                               
102 Hestermeyer (fn 71 above) 11. 
103 See Thomas and Meyer (fn 8 above) 256.  
104 Ibid 252. 
105 Correa (fn 100 above) 8. 
106 Velasquez and Boulet (fn 100 above) 40. See also Correa (fn 100 above) 8. 
107 Correa (fn 100 above).  
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transitional arrangements. Article 1 sets out the nature and scope of the obligations 
under the Agreement stating that Members shall give effect to its provisions and 
that they may provide more extensive protection than the minimum set by the 
Agreement. It further states that Members are at liberty to determine “the 
appropriate method” of implementing TRIPS provisions “within their own legal 
systems and practice”. 
 The objectives of the TRIPS Agreement as set out in article 7 essentially focus on 
contributing “to the promotion of technological innovation and to the transfer and 
dissemination of technology … in a manner conducive to social and economic 
welfare, and to a balance of rights and obligations”.108 In terms of article 8 (which 
clarifies the application, scope and coverage of the Agreement) Members are free to 
adopt measures relating to public health and nutrition or to promote the public 
interest in certain sectors provided that such measures are consistent with the 
Agreement. Further, the provision allows Members to adopt measures to prevent 
anti-competitive abuse of intellectual property rights by right holders. 
 Part II of the Agreement provides for minimum standards of protection that WTO 
Members must respect concerning the availability, scope and use of specific 
categories of intellectual property rights taking into account the national treatment 
and MFN principles which are set out in articles 3 and 4. The agreement protects 
seven types of intellectual property: patents, copyright, trademarks, industrial 
designs, geographical indications, layout designs of integrated circuits and 
undisclosed information.109 The most important of these from the perspective of 
access to medicines are the provisions concerning patents.  
 Part III of the Agreement establishes specific obligations concerning the 
enforcement of the protections provided for intellectual property. In particular, it 
specifies a number of rights and remedies that Members must extend to right-
holders under their domestic laws.110 Part IV concerns dispute prevention and 
settlement while part VI provides for transitional arrangements. 
(b) Human Rights Implications 
The TRIPS Agreement is one of the most controversial agreements under the WTO 
in terms both of its objectives and consequences. It has a number of implications for 
public health, food security, biodiversity, agriculture and indigenous knowledge.111 
                                               
108 The protection of intellectual property rights was introduced into the agenda of the WTO 
ostensibly to protect innovation by giving temporary monopolistic rents to innovative companies 
which are mainly located in the developed countries – in reality to protect the high-tech industries of 
developed countries from developing country competition, particularly from South East Asia. See 
McCulloch Winters and Cirera (fn 24 above) 208. According to Oxfam, the claims that intellectual 
property protection and the resulting monopoly profits can sustain innovation are debatable. See 
Oxfam (2006) fn 4 above at 6-8. 
109 Arts 15-40. 
110 Arts 42-61. 
111 See UNDP Human Development Report (1999). 
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All of these relate to the human rights standards set out in international human 
rights instruments, most notably, in articles 11 to 15 of the International Covenant 
on Economic, Social and Cultural Rights (ICESCR). In a resolution adopted in August 
2000, the Sub-Commission on the Promotion and Protection of Human Rights noted 
the following: 
[A]ctual or potential conflicts exist between the implementation of the TRIPS 
Agreement and the realisation of economic, social and cultural rights in relation to, 
inter alia, impediments to the transfer of technology to developing countries, the 
consequences for the enjoyment of the right to food, of plant variety rights and the 
patenting of genetically modified organisms, ‘bio-piracy’ and the reduction of 
communities’ (especially indigenous communities’) control over their own genetic 
and natural resources and cultural values, and restrictions on access to patented 
pharmaceuticals and the implications for the enjoyment of the right to health.112 
 
 The Sub-Commission proceeded to declare that:  
[S]ince the implementation of the TRIPS Agreement does not adequately reflect the 
fundamental nature and indivisibility of all human rights, including the right of 
everyone to enjoy the benefits of scientific progress and its applications, the right to 
health, the right to food, and the right to self-determination, there are apparent 
conflicts between the intellectual property rights regime embodied in the TRIPS 
Agreement, on the one hand, and international human rights law, on the other.113  
 
 It further requested “the World Trade Organisation, in general, and the Council 
on TRIPS during its ongoing review of the TRIPS Agreement, in particular”, to take 
fully into consideration “the existing State obligations under international human 
rights instruments”.114 
 What follows is a discussion of the implications of TRIPS for the realisation of the 
right to health in general and access to medicines in particular. 
(c) TRIPS and the Right to Health 
The right to health is a fundamental human right which is indispensable for the 
enjoyment of other rights. While it is generally considered to be part of the group of 
economic, social and cultural rights (as opposed to civil and political rights) the 
right to health is closely related to and dependent upon the realisation of other 
human rights, including the rights to food, housing, work, education, human dignity, 
non-discrimination, equality, life, privacy, access to information, and the prohibition 
of torture. 
 First explicitly formulated as a “right” in the Preamble to the Constitution of the 
World Health Organisation (WHO) in 1946, the right to health has been 
                                               
112 Resolution on Intellectual Property Rights and Human Rights, Doc.E/CN.4/Sub.2/2000/7, 17 
August 2000, preamble. 
113 Ibid para 2. 
114 Ibid para 8. 
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incorporated in varying formulations in a wide range of international legal 
instruments. The main universal human rights instruments providing for the right 
to health include the Universal Declaration of Human Rights (UDHR);115 the 
ICESCR;116 Convention on the Elimination of All Forms of Discrimination against 
Women (CEDAW);117 Convention on the Rights of the Child (CRC);118 Convention on 
the Elimination of All Forms of Racial Discrimination (ICERD);119 Convention on the 
Protection of the Rights of All Migrant Workers and Members of their Families 
(CMW),120 and the Convention on the Rights of People with Disabilities.121 Other 
international instruments relating to, or enshrining the right to health are the 
Geneva Conventions of 1949122 and  the Additional Protocols of 1977123 which 
oblige States Parties to provide medical care for the wounded; the Declaration on 
the Protection of Women and Children in Emergency and Armed Conflict; the Body 
of Principles for the Protection of All Persons Under Any Form of Detention or 
Imprisonment; the Standard Minimum Rules for the Treatment of Prisoners; the 
Declaration on the Rights of Mentally Retarded Persons; and the Declaration on the 
Rights of Disabled Persons. 
 Article 12 of the ICESCR provides that everyone has the right “to the highest 
attainable standard of physical and mental health”. In terms of article 12(2) (c), 
States Parties must take the necessary steps for “the prevention, treatment and 
control of epidemic, endemic, occupational and other diseases”. The ESCR 
Committee has interpreted this provision to mean the establishment of prevention 
and education programmes for behaviour-related health concerns such as sexually 
transmitted diseases, in particular HIV/AIDS, and those adversely affecting sexual 
and reproductive health, and the promotion of social determinants of good health, 
such as environmental safety, education, economic development and gender 
                                               
115 Article 25. 
116 Article 12. 
117 Article 12 guarantees to women the right to health care, focusing on equal access to health care 
facilities for women. In particularly, it provides for the provision free of charge of pre and post natal 
healthcare by states. Article 12(d) enjoins states to ensure that rural women have “access to health 
care facilities, including information, counselling and services in family planning”. 
118 Article 24 guarantees the right of children to “the highest attainable standard of health”.  
119 Article 5(e) (IV) guarantees the right of everyone, without distinction as to race, colour or national 
or ethnic origin, among others, the right to public health and medical care. 
120 Article 27 enjoins states parties to provide emergency medical care to migrant workers and 
members of their families. 
121 Article 25 guarantees the right of persons with disabilities to enjoy the highest attainable 
standard of health without discrimination on the basis of disability. 
122 Article 3(2) of the Convention (I) for the Amelioration of the Condition of the Wounded and Sick in 
Armed Forces in the Field; Convention (II) for the Amelioration of the Condition of the Wounded, Sick 
and Shipwrecked Members of the Armed Forces at Sea; Convention (III) relative to the Treatment of 
Prisoners of War; and Convention (IV) relative to the Protection of Civilian Persons in Time of War. 
The four conventions were adopted on 12 August 1949. 
123 Protocol Additional to the Geneva Conventions of 12 August 1949, and Relating to the Protection 
of Victims of International Armed Conflicts (Protocol I), articles 10 and 11 and Protocol Additional to 
the Geneva Conventions of 12 August 1949, and Relating to the Protection of Victims of Non-
International Armed Conflicts (Protocol II), article 7. Both Protocols were adopted on 8 June 1977. 
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equity.124 The control of diseases concerns states’ duties (individually and 
collectively) to make available relevant technologies, the implementation or 
enhancement of immunizations programmes and other strategies for controlling 
infectious diseases.125 Under article 12(2)(d) of the ICESCR, States Parties must 
create “conditions which would ensure to all medical attention in the event of 
sickness”. According to General Comment No 14 adopted by the ESCR Committee, 
this includes, inter alia, the provision of essential drugs.  
 The ESCR Committee has identified four interrelated and essential elements of 
the right to health: availability of sufficient and functioning public health and health-
care facilities, goods and services; accessibility of health facilities, goods and services 
to everyone on a non-discriminatory basis; acceptability (or cultural 
appropriateness) of health facilities, goods or services; and quality of health 
facilities, goods and services (which must be scientifically and medically appropriate 
and of good quality).  
 In the context of the current discussion, the concept of accessibility implies that 
government policies must aim to make drugs available for all who need them, and at 
affordable prices.126  
(d) Constraints on Access to Medicines 
As stated above, accessibility is one of the key elements of the right to health. Based 
on human rights principles, universal access requires that medicines not only be 
available,127 acceptable and of good quality, but also affordable to all. However, in 
many developing countries there are numerous existing barriers to access to 
appropriate health care. These include non-affordability of drugs, poor health care 
infrastructure, poor diagnosis, and inadequate funding.128 It is important to note in 
                                               
124 See CESCR General Comment No 14: The Right to the Highest Attainable Standard of Health, 
Doc.E/C.12/2000/4 (2000) para 16. 
125 Ibid. 
126 In 2001, the UN General Assembly unanimously embraced equitable access to care and treatment 
as a fundamental component of a comprehensive and effective global HIV response. See UN 
Declaration of Commitment on HIV/AIDS, Resolution adopted by the General Assembly, Doc.A/Res/S-
26/2, 2 August 2001. 
127 In Free Legal Assistance Group and Others v Zaire (2000) AHRLR 74 (ACHPR 1995), the African 
Commission on Human and Peoples’ Rights found, inter alia, that the shortage of medicine 
constituted a violation of the right to enjoy the best attainable state of physical and mental health. 
The Commission endorsed the definition of the right to health put forth by the UN Committee on the 
Elimination of Discrimination against Women. In its General Recommendation No 24, the Committee 
defined the right to health to include socio-economic factors: “The Committee notes that the full 
realisation of women’s right to health can be achieved only when States parties fulfil their obligations 
to respect, protect and promote women’s fundamental human right to nutritional well-being 
throughout their life-span by means of a food supply that is safe, nutritious and adapted to local 
conditions”.  
128 Dommen (fn 2 above) 23. See also Mushayavanhu D “The realisation of access to HIV and AIDS-
related medicines in Southern African countries: Possibilities and actual realisation of international 
law obligations” in Viljoen F and Precious S (eds) Human Rights under Threat: Four Perspectives on 
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this regard that a country’s level of development does not relieve it of responsibility 
to ensure full realisation of the right to health. Thus, in Purohit and Moore v The 
Gambia,129 the African Commission on Human and Peoples’ Rights held that while 
many African countries faced the “problem of poverty” which rendered them 
incapable of providing the necessary amenities, infrastructure and resources that 
facilitate the full enjoyment of the right to health, article 16 of the Charter imposed 
an obligation on the part of States parties to “take concrete and targeted steps, while 
taking full advantage of their available resources” to ensure that the right to health 
is fully realised in all its aspects without discrimination of any kind.  
 Although the precise effect of the TRIPS Agreement may vary from country to 
country, it has been asserted that patent protection enhances the likelihood of 
higher drugs prices.130 Numerous empirical studies concerning the price effects of 
patents indicate that patents lead to significant price increases which are generally 
in excess of 100 per cent.131 In a complaint lodged in 2002 by the AIDS Law Project 
with the South African Competition Commission alleging that GlaxoSmithKline and 
Boehringer Ingelheim were acting in violation of the Competition Act No 89 of 1998 
by charging excessive prices for their anti-retroviral drugs (ARVs) to the detriment 
of consumers, the complainants submitted that a comparative analysis of the 
patented medicines and generic alternatives indicated that the patented drug was 
generally priced at 230 per cent of the generic.132 
 The observations of international organisations with responsibilities in the area 
of health lend succour to the foregoing claims. For example, UNAIDS has stated that 
patents have had “a severely limiting effect on access to medicines because prices 
                                                                                                                                            
HIV, AIDS and the Law in Southern Africa (2007) 127, 130. 
129 (2003) AHRLR 96 (ACHPR 2003). 
130 Velasquez and Boulet (fn 100 above) 89. In circumstances where the technology of essential drugs 
(such as ARVs), is controlled by a few pharmaceutical companies in the developed countries that 
tend to charge prices well beyond what poor people can afford, TRIPS requirements have serious 
implications for human rights. As Baker has observed, the overall effect of the Agreement has been 
“to consolidate the economic power and exclusive marketing privileges” enjoyed by the 
pharmaceutical industry. See Baker BK Processes and Issues for Improving Access to Medicines: 
Willingness and Ability to Utilise TRIPS Flexibilities in Non-Producing Countries (2004)15.  
131 These indicate that patents lead to significant price increases, generally in excess of 100 per cent. 
See, for example, Chaudhuri S Goldberg PK and Jia P “The Effects of Extending Intellectual Property 
Rights Protection to Developing Countries: A Case Study of the Indian Pharmaceutical Market” NBER 
Working Paper 10159 (2003) 31 (price increases for India estimated at between 200% and 750%); 
Fink C “How Stronger Patent Protection in India Might Affect the Behaviour of Transnational 
Pharmaceutical Industries” World Bank Working Paper No 2352 (2000) 42 (Indian price increases 
estimated at over 200%); Correa CM Intellectual Property Rights, the WTO and Developing Countries: 
The TRIPS Agreement and Policy Options (2000) 35; Subramanian ”The AIDS Crisis, Differential 
Pricing of Drugs and the TRIPS Agreement: Two Proposals” (2001) 4 Journal of World Intellectual 
Property  323, 324. 
132 See AIDS Law Project and TAC The Price of Life: Hazel Tau and Others v GlaxoSmithKline and 
Boehringer Ingelheim: A Report on the Excessive Pricing Complaint to South Africa’s Competition 
Commission (2003). 
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have been set that are far beyond the reach of developing countries”.133 Similarly, 
the WHO has observed that patents “can play a significant, or even dominant, role” 
in preventing access to medicines in that they grant the patent holder a monopoly 
on a drug for the duration of the patent.134 While acknowledging that the price of 
ARVs “has fallen significantly in recent years”, the WHO has emphasised that the 
cost of these drugs “remains an obstacle to access in the developing world”. By 
December 2006, between 1.8 – 2.2 million people were receiving anti-retroviral 
treatment in low- and middle income countries, representing 28 per cent of the 
estimated 7.1 million people in need.135  
 The high cost of pharmaceuticals poses a threat to the right to health by 
restricting access to medicines for poor consumers from developing countries.136 In 
relation to HIV/AIDS, patented versions of ARVs and other drugs used against the 
attendant opportunistic infections typically cost almost 15 times as much as their 
generic equivalents. In countries with severe health budgetary constraints, these 
prices almost invariably entail the exclusion of large numbers from effective 
treatment.137  It can be contended therefore that the TRIPS Agreement essentially 
impairs the right to health by hindering the ability of governments to fulfil their 
obligations to their citizens with respect to ensuring access to affordable medicines. 
It is in recognition of this reality that the General Council of the WTO adopted the 
Declaration on TRIPS and Public Health. 
 
4.4 Pharmaceutical Patents Flexibilities under TRIPS  
The TRIPS Agreement provides for measures that limit the rights of patent 
holders.138 These include limited exceptions under article 30 of the Agreement, 
compulsory licences, parallel imports and patent revocation in terms of article 32 of 
the Agreement.139 These “TRIPS flexibilities”, as they are commonly referred to, are 
significant from the perspective of the right to health in that they can enhance the 
ability of WTO Member States to ensure access to affordable medicines.   
                                               
133 See http://www.unaids.org/eng/PolicyAndPractice/HIVTreatment/IntellectProperty/ (access 
confirmed: 16 February 2008).  
134 See WHO/UNAIDS/MSF “Determining the patent status of essential medicines in developing 
countries” Health Economics and Drugs, EDM Series, No 17 (2004), WH/EDM/PAR/2004.6, at 7. 
135 WHO/UNAIDS/UNICEF Towards Universal Access: Scaling up priority HIV/AIDS interventions in the 
health sector, Progress Report (2007) 5. 
136 According to OHCHR, highly priced drugs have negative implications for the right to health. 
OHCHR (fn 95 above) 2. See also Eide A “The Importance of Economic and Social Rights in the Age of 
Economic Globalization” in Eide WB and Kracht U (eds) Food and Human Rights in Development: 
Legal Institutional Dimensions and Selected Topics Vol I (2005) 3, 35. 
137 Oxfam (2001) fn 4 above. 
138 A Member State’s freedom to interpret and use these flexibilities to promote public health was 
reaffirmed by the 2001 WTO Doha Declaration on TRIPS and Public Health (discussed below). 
139 For a discussion of these flexibilities, see Hestermeyer (fn 71 above) 229-255; Mushayavanhu (fn 
128 above)  




(a) Limited Exceptions 
In terms of article 30 of the Agreement, Members may provide several exceptions to 
the exclusive rights conferred by patents “provided that such exceptions do not 
unreasonably conflict with a normal exploitation of a patent and do not 
unreasonably prejudice the legitimate interests of the patent owner”. While some 
commentators have favoured a broad interpretation of this provision, in Canada-
Pharmaceuticals, the Panel held that the limitations and exceptions permitted under 
article 30 had to fulfil three separate, cumulative criteria: (a) the exception must be 
limited or narrow in scope; (b) the exception must not unreasonably conflict with 
normal exploitation of the patent (i.e. the patent owner had the right to “exclude all 
form of competition that could detract significantly from the economic return 
anticipated from a patent’s grant of market exclusivity”); and (c) the exception must 
not unnecessarily prejudice the legitimate interest of the patent owner, taking into 
account the legitimate interests of third parties.140 The Panel distinguished the 
concept of legitimate interests from that of “legal interests”, holding that the latter 
was narrower than the former and, that the former referred to “interests that are 
‘justifiable’ in the sense that they are supported by relevant public policies or other 
social norms”.141   
 Nevertheless, it is important to note that the provision does not stipulate the 
various grounds on which Members may base their exceptions. Thus, Member States 
have wide latitude for implementing the Agreement through national laws. In this 
regard, it is worth recalling that under article 8(1) of the TRIPS Agreement, a 
Member State may adapt national regulations to the fundamental objectives of its 
policies in certain areas, provided these regulations do not contravene the 
provisions of the Agreement. Among these objectives are “public health” and 
nutrition. In terms of this provision: 
Members may, in formulating or amending their laws and regulations, adopt 
measures necessary to protect public health and nutrition, and to promote the 
public interest in sectors of vital importance to their socio-economic and 
technological development, provided that such measures are consistent with the 
provisions of this Agreement. 
 
 It is arguable that the above provision constitutes an express recognition of 
measures that a Member State could adopt to guarantee accessibility to medicines. 
In other words, the provision affords Member States the opportunity to establish 
national regulations designed to guarantee access to essential and affordable 
drugs.142 
                                               
140Canada-Patent Protection of Pharmaceutical Products - Complaint by the European Communities 
and their Member States, WT/DS114/R, par 7.20 (2000). 
141 Ibid at par 7.69. 
142 Velasquez and Boulet (fn 100 above) 19. 
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(b) Compulsory Licences 
In general, patent holders are free to exploit the patented invention or to authorize 
someone else to exploit it. Under article 31, however, Member States may issue 
compulsory licences when reasons of general or public interest (such as public 
health, economic development and national defence) justify it. Stated differently, 
governments may allow the exploitation of a patent by a third party without the 
patent holder’s consent provided the minimum conditions stipulated by the 
Agreement which are aimed at protecting the legitimate interests of the patent 
holder are satisfied.143 Thus, for instance, the applicant for a licence must have first 
attempted, unsuccessfully, to obtain a voluntary licence from the right holder on 
reasonable commercial terms.144 If a compulsory licence is issued, adequate 
remuneration must still be paid to the right holder.145 
 However, it is not necessary to apply for a voluntary licence in cases of “national 
emergencies”, “other circumstances of extreme urgency” or “public non-commercial 
use” (or “government use”) or anti-competitive practices.146 The Doha Declaration 
recognises that public health crises, such as those relating to HIV/AIDS, 
tuberculosis, malaria and other epidemics, can represent a national emergency or 
“other circumstances of extreme urgency”.147 Thus, it can be argued that ensuring 
the availability of essential drugs at lower cost is a public interest issue.  
 Compulsory licensing allows governments to make generic versions of patented 
drugs available and may therefore have the effect of reducing the price of medicines 
and ensuring access to affordable medicines. Nevertheless, many countries have 
                                               
143 The minimum conditions set by the Agreement are: authorization will be granted only if the 
proposed user has attempted to obtain the licence on reasonable commercial terms; the scope and 
duration of the authorization must be limited; authorization is non-exclusive; the authorization 
cannot be assigned; the main objective of the authorization must be supply of the domestic market; 
the authorization will be suspended if the circumstances that led to it cease to exist; and the patent 
holder must be given adequate remuneration that takes into consideration the economic value of the 
authorization. It should be noted that the term “compulsory licensing” is not used in the TRIPS 
Agreement. Instead, article 31 refers to “other use without authorization of the right holder”. 
Conversely, the Doha Declaration employs the term “compulsory licences” in article 5(b) which 
confers upon Members the right to grant compulsory licences and to determine the grounds upon 
which such licences are granted. 
144 Article 31(b). 
145 Article 31(h). Nevertheless, as the Zambian case illustrates, a developing country responding to a 
public health crisis can determine a relatively low rate of remuneration to be adequate. In September 
2004, Zambia granted a compulsory licence on medicine (the first granted by an African country) to a 
local company for the production of a triple-combination AIDS drug after the failure of negotiations 
with the patent holders. Zambia fixed the royalties at a rate not exceeding 2.5 per cent of the total 
sales of the product at the end of each financial year. See Republic of Zambia Ministry of Commerce, 
Trade and Industry Compulsory Licence No CL 01/2004, MCT1/104/1/1c (21 September 2004) cited 
in Hestermeyer (fn 71 above) at 249. 
146 Article 31(b). 
147 Doha Declaration, article 5(c). 
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failed to utilise this flexibility due to the uncertainty concerning the interpretation 
of the conditions imposed by article 31 of TRIPS and the pressure applied by 
developed countries not to grant compulsory licences for pharmaceuticals.148 
Further, countries with no production capabilities are disadvantaged in that they 
cannot issue effective compulsory licences because of the requirement under article 
31(f) that production under such a licence should be “predominantly for the supply 
of the domestic market”. 
(c) Parallel Imports 
Parallel imports are products marketed by the patent owner or with the patent 
owner’s permission in one country and imported into another country without the 
approval of the patent owner.149 This flexibility is based on the theory of exhaustion 
of intellectual property rights according to which the exclusive right of the patent 
holder to import the protected product is exhausted, and thus ends, when the 
product is first put on the market. While the principle is uncontested in the national 
context it has generated a great deal of controversy in the international context.150 It 
is notable, however, that the TRIPS Agreement does not explicitly mention or ban 
parallel imports. This lacuna gives Members wide latitude to determine their own 
regulatory regimes. 
 As in the case of compulsory licenses, parallel imports can have the effect of 
reducing the price of medicines by allowing the government to grant a licence for 
the import of cheaper versions of a patented drug.  
(d) Revocation of Patents 
In some cases, national patent laws provide for the revocation of or forfeiture of a 
patent in circumstances where the maintenance fees are not paid timely or where 
the conditions for the grant of a patent were not fulfilled at the time of the grant. 
Article 32 of TRIPS implicitly recognises the right of Member States to revoke 
patents by providing that “[a]n opportunity for judicial review of any decision to 
revoke or forfeit a patent shall be available”. However, the provision does not 
specify the grounds of any such revocation or forfeiture. This has led to different 
interpretations with some Member States (such as India) arguing that the provision 
allows the revocation of patents on any grounds and others (such as the US) 
countering that such an interpretation is inconsistent with the TRIPS Agreement.151 
Nevertheless, it may be argued that the revocation of a patent can potentially lower 
drug prices by allowing competition and in this way enhancing access to affordable 
medicines. 
 
                                               
148 Hestermeyer (fn 71 above) 253. 
149 Velasquez and Boulet (fn 100 above). 
150 See Hestermeyer (fn 71 above) 230. 
151 Hestermeyer (fn 71 above) 253-254. 
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4.5 Obstacles to using TRIPS Flexibilities 
It is worthy of note that while a number of developing countries have attempted to 
invoke the TRIPS flexibilities to advance public health goals, they generally have 
encountered obstacles in the form of legal challenges by developed countries, 
notably the US. The South African and Brazilian attempts to ensure their citizens’ 
access to affordable medicines are instructive. 
 In 2002, the South African government passed the Medicines and Related 
Substances Act Control Amendment Act152 in response to the HIV/AIDS epidemic 
and to keep medicines affordable in the country. Under section 15C of the Act the 
Minister of Health was empowered to limit patent rights through the use of two 
measures designed to ensure access to cheaper medicines: parallel imports and 
compulsory licences. In response, several large pharmaceutical transnational 
corporations (TNCs) instituted suit against the government, arguing that many 
provisions of the Act contravened, inter alia, the pharmaceutical industry’s property 
rights under the South African Constitution.153 It was also contended that section 
15C was inconsistent with article 27 of the TRIPS Agreement as it purportedly 
discriminated against pharmaceutical patents. Conversely, the South African 
government argued that it had a constitutional obligation to protect its citizens’ 
right to health. For its part, the US government placed South Africa on its “Special 
301” Watch List and withheld preferential treatment under the Generalized System 
of Preferences on selected items. However, intense national and international 
pressure forced the TNCs to withdraw their lawsuit and the US government to reach 
an agreement with the South African government.154 
 In 2001, the US initiated a WTO dispute settlement proceeding against Brazil 
concerning the latter’s compulsory licensing legislation, which imposed a “local 
working” requirement, stipulating that a patent would be subject to compulsory 
licensing if the subject matter was not “worked” in Brazil.155 The US claimed that 
this requirement discriminated against US companies which owned Brazilian 
patents whose products were imported into, but not produced, in Brazil. The US 
alleged that this law was incompatible with the TRIPS Agreement. Brazil had 
produced generic anti-retroviral drugs (ARVs) without using compulsory licences 
because pharmaceutical patents were not recognised. However, the new legislation 
                                               
152 Act No 90 of 1997. 
153 Pharmaceutical Manufacturers’ Association of South Africa et al v President of the Republic of South 
Africa, Case No. 4183/98. 
154 The understanding was premised on the commitment of both governments to TRIPS as well as “an 
appreciation of the South African Government’s efforts to provide affordable health care to its 
people”. See Department of Trade and Industry Joint Understanding between the Governments of 
South Africa and the United States of America available at http://lists.essential.org/pharm-
policy/msg00244.html (access confirmed: 28 March 2008). 
155 Industrial Property Law, Law 9.279/96. See Request for Consultations by the United States, Brazil-
Measures Affecting Patent Protection, WT/DS199/1, G/L/385, IP/D/23, 8 June 2000, and Request for 
the Establishment of a Panel by the United States, Brazil-Measures Affecting Patent Protection, 
WT/DS199/39, January 2001. 
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brought Brazil in line with its WTO obligations. In order to produce new generic 
ARVs, the Brazilian government had to issue compulsory licences under the 
legislation challenged by the US. Needless to mention, the measures demanded by 
the US posed a direct threat to the highly successful Brazilian government 
programme to fight HIV/AIDS, which was largely based on Brazil’s ability to 
manufacture affordable drugs for HIV/AIDS treatment. Ultimately, however, the 
parties reached a “mutually satisfactory” political settlement in which the US 
withdrew the case and Brazil agreed, in the event “it deems necessary to apply 
article 68 (of its Industrial Property Law) to grant compulsory licence on patents 
held by the US companies and to hold prior talks on the matter with the US 
Government”.156 However, the US reserved its right to re-introduce the issue and 
threatened to “aggressively engage” any other countries that sought to utilise the 
“local working” requirement.157 
 
4.6 The Doha Declaration – a Way out of the Quagmire? 
In November 2001, the flexibility under TRIPS was clarified and enhanced by the 
Doha Ministerial Declaration which addressed the issue of the relationship between 
the TRIPS Agreement and access to medicines.158 The Declaration, which was 
adopted in response to the multiple controversies concerning access to drugs, 
especially in the context of the HIV/AIDS epidemic, recognised that: 
[U]nder WTO rules no country should be prevented from taking measures for the 
protection of human, animal or plant life or health, or of the environment at the 
levels it considers appropriate, subject to the requirement that they are not applied 
in a manner which would constitute a means of arbitrary or unjustifiable 
discrimination between countries where the same conditions prevail, or a disguised 
restriction on international trade, and are otherwise in accordance with the 
provisions of the WTO Agreements.159 
 
Paragraph 17 of the Declaration underlined the importance of implementing and 
interpreting the TRIPS Agreement in a manner that supports public health, by 
promoting both access to existing medicines and the development of new medicines. 
 In recognition of the “gravity of the public health problems afflicting many 
developing and least developed countries”, the Ministers also adopted a separate 
Declaration on TRIPS and Public Health which asserted that the TRIPS Agreement 
does not and should not hinder the efforts of WTO Member States aimed at 
                                               
156 See Joint Communication, Brazil-United States, 25 June 2001. 
157 The US has applied pressure on other WTO Members, forcing them to change their policies. These 
include Argentina, the Dominican Republic, Kenya and Thailand. See Abbott FM “The Doha 
Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO” (2002) 
Journal of International Economic Law 469, 472.  
158 Document WT/MIN(01)/DEC/1, 20 November 2001. 
159 Ibid at para 6. 
LAW, DEMOCRACY & DEVELOPMENT / VOL 14 (2010) 
 14 
protecting public health.160 The Declaration also reaffirmed the right of developing 
countries to employ safeguards under the Agreement to reduce the price of 
medicines and further requested WTO Members to find a solution for countries with 
insufficient generic manufacturing capacity.161 The LDC Members were afforded, on 
a without prejudice basis, an exemption from implementing or applying sections 5 
and 7 of Part II of the TRIPS Agreement concerning pharmaceutical patents until 1 
January 2016. 
 In August 2003, the TRIPS flexibility enhancement concerning pharmaceutical 
patents was implemented by a WTO decision allowing developing countries that do 
not have the capacity to manufacture pharmaceuticals to import cheap generic 
drugs made under compulsory licence in order to address public health 
problems.162 In December 2005, the General Council of the WTO took a decision 
which effectively transforms the August 2003 decision (termed the “paragraph 6 
system”) into a permanent amendment of the TRIPS Agreement.163 The amendment 
will enter into force once two thirds of WTO Members have ratified it by the 
extended deadline of 31 December 2011.164 Until then, Members can still utilise the 
August 2003 decision as it stands. Although this mechanism is a potentially 
significant measure, it has been criticised by a number of organisations advocating 
access to medicines for being “too burdensome and unworkable in practice”.165 
 It has been contended further that the spirit and purpose of the Doha Declaration 
has been frustrated by the proliferation of free trade agreements (FTAs) which 
enjoin developing countries not to utilise TRIPS flexibilities or burden developing 
countries with unacceptably high standards of intellectual property protection 
                                               
160 Document WT/MIN(01)/DEC/2, paras 1 and 4. Cf. EC-Measures affecting asbestos and asbestos-
containing products, WT/DS135/AB/R, 12 March 2001, para 168, where the WTO Appellate Body 
upheld the right of Member States “to determine the level of protection of health that they consider 
appropriate in a given situation”.  
161 Ibid at paras 4 and 6.On 17 July 2007, Rwanda became the first Member State to inform the WTO 
that it was using the 30 August 2003 decision designed to ease the way for countries with public 
health problems to import cheaper generic drugs made under compulsory licensing in other 
countries when they are unable to manufacture the drugs themselves. 
162 Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health,  
Decision of the General Council of 30 August 2003, Document WT/L/540 and Corr.1, 1 September 
2003. The measure is known as the “paragraph 6 system”. On 17 July 2007, Rwanda became the first 
Member State to inform the WTO that it was using the 30 August 2003 decision designed to ease the 
way for countries with public health problems to import cheaper generic drugs made under 
compulsory licensing in other countries when they are unable to manufacture the drugs themselves.  
163 Amendment of the TRIPS Agreement, Decision of 6 December 2005, Document WT/L/641, 8 
December 2005. 
164 As of 17 September 2010, only 31 of the WTO’s 153 Members had ratified the amendment: 
Albania, Australia, Bahrain, Brazil, Canada, China, Colombia, Egypt, El Salvador, Hong Kong (China), 
India, Israel, Japan, Jordan, Macau (China), Mauritius, Mexico, Mongolia, Morocco, Nicaragua, Norway, 
Pakistan, Philippines, Republic of Korea, Singapore, Switzerland, Uganda, the Former Yugoslav 
Republic of Macedonia, the European Union (formerly the European Community), the US and Zambia. 
165 See Joint Statement by NGOs on TRIPS and Public Health, WTO Members should reject bad deal on 
medicines, 3 December 2005 available at http://www.cptech.org/ip/wto/p6/ngos12032005.html 
(access confirmed: 28 March 2008). 
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which far exceed the TRIPS standards (termed “TRIPS-plus” rules or conditions).166 
Common restrictive measures in FTAs include the explicit limitation of TRIPS 
flexibilities or imposition of additional obligations, extension of patent terms, grant 
of “new use” patents, parallel import bans, and limitation of the grounds for 
issuance of compulsory licences.167 These measures can undermine Member States’ 
obligations to ensure the enjoyment of the rights to health and life by making 
medicines more expensive. An example is the United States–Morocco Free Trade 
Agreement that was signed in March 2004 amidst severe criticism and entered into 
force on 1 January 2006. The FTA includes intellectual property rules that extend 
well beyond the TRIPS standard.168 These “TRIPS-plus” rules involve the extension 
of patent term, limitations on parallel imports of patented drugs, data exclusivity 
and market authorization restrictions.169 The FTA thus undermines the flexibilities 
reaffirmed by the Doha Declaration on TRIPS and Public Health and restricts 
Morocco’s ability to take measures designed to reduce the cost of medicines and to 
ensure access to these by the poorest sections of its population. 
 In sum, while the Declaration can potentially mitigate the harmful effects of 
intellectual property rules, developed countries and the pharmaceutical companies 
have undermined its effectiveness in a variety of ways.  
 
4.7 The Agreement on Agriculture and Human Rights 
The Agreement on Agriculture (AoA) entered into force in 1995 as part of the WTO 
system.170 It is designed to further the aims of the organisation by “establishing a 
fair and market-oriented agricultural trading system”.171 The Agreement includes 
specific commitments by Member States to enhance market access and reduce 
                                               
166 Hestermeyer (fn 71 above). See also Oxfam (2006) fn 4 at 12-18. Between 2001 and 2006, the US 
had concluded 11 bilateral and regional FTAs with 23 countries. See Correa CM “Implications of 
Bilateral Free Trade Agreements on Access to Medicines” (2006) 84 Bulletin of the WHO 399 cited in 
Hestermeyer (fn 71above) at 289. The US has also applied other forms of pressure on developing 
countries to implement higher levels of intellectual property protection including monitoring other 
countries’ intellectual property rules in relation to US standards (Special 301 reports) and 
introducing TRIPS-plus rules which makes the WTO accession process almost impossible for new 
members.  
167 Examples of these provisions include the US-Chile FTA, article 17.10.2(a) (extension of patent 
term); US-Morocco FTA, article 15.9.2 (“new use” patents); US-Morocco FTA, article 15.9.4 and US-
Australia FTA, article 17.9.4 (ban on parallel imports); and US-Jordan FTA, article 4.20 (grounds for 
compulsory licences). 
168 3D Trade-Related Intellectual Property Rights, Access to Medicines and Human Rights – Morocco 
(2006) 3. 
169 Ibid 4. 
170 The Agreement is set out in Annex 1A to the Marrakesh Agreement. 
171 Preamble to Agreement on Agriculture, para 2. See also Wouters and De Meester (fn 8 above) at 
89-94; Bhala R “World Agricultural Trade in Purgatory: the Uruguay Round Agriculture Agreement 
and its Implications for the Doha Round” (2003) North Dakota Law Review 691-830; O’Connor B “A 
Note on the Need for More Clarity in the World Trade Organization Agreement on Agriculture” 
(2003) Journal of World Trade 839-846.  
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trade-distorting subsidies in agriculture.172 Members were enjoined to implement 
these commitments over a six-year period (10 years for developing countries) 
which commenced in 1995.  
(a) Overview of Main Provisions 
The provisions of the AoA are in three main categories: market access,173 domestic 
support174 and export subsidies.175 First, the AoA seeks to increase international 
agricultural trade by reducing tariffs (i.e. border obstacles to trade such as taxes and 
duties). In this regard, Members are required to abolish restrictions on the quantity 
of agricultural products entering their markets (“quantitative restrictions”) and not 
to maintain, resort to, or revert to any measures of the kind which have been 
required to be converted into ordinary customs duties, including variable import 
levies, minimum import prices, discretionary import licensing, non-tariff measures 
maintained through state-trading enterprises, voluntary export restraints or similar 
border measures.176 Under article 5, Members can indicate in their schedules that 
they regard certain agricultural products as potentially subject to “special safeguard 
provisions” which can be used to prevent import surges or drops in prices. A 
notable aspect of the market access commitments is that all Members, including the 
LDCs, have to bind all tariffs on agricultural products. 
 Second, article 6 of the AoA aims to reduce the level of domestic support 
provided by governments to their farmers since these directly distort trade and 
production.177 Such support includes subsidies for production of specific 
agricultural goods, guaranteed prices and agricultural infrastructure and research.  
Least developed countries have no reduction commitments.  
 Finally, article 9 of the AoA specifies export subsidies – government payments 
that cover the costs of exporting agricultural produce178 – which WTO Members are 
enjoined to reduce. It also prohibits the introduction of new subsidies. Again, LDC 
Members have no commitments in this regard. 
 Despite the commitments made by WTO Members under the Doha Declaration of 
14 November 2001 concerning negotiations aimed at substantial improvements in 
market access reductions of all forms of export subsidies and substantial reductions 
in trade-distorting domestic support; as well as their agreement that special and 
                                               
172 Wouters and De Meester (fn 8 above) 89. 
173 Article 4. 
174 Article 6. 
175 Article 8. 
176 In Chile-Price Band System and Safeguard Measures Relating to Certain Agricultural Products, 
WT/DS207/AB/R, par 200-201 (2002), the Appellate Body indicated that article 4 is “appropriately 
viewed as the legal vehicle for requiring the conversion into ordinary customs duties of certain 
market access barriers affecting imports of agricultural products”. 
177 Wouters and De Meester (fn 8 above) 90. 
178 See Canada – Measures Affecting the Importation of Milk and the Exportation of Dairy Products 
(Canada – Dairy), WT/DS103/AB/R, par. 87 (1999). 
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differential treatment for developing countries would constitute an integral part of 
the negotiations, there has not been much progress made in this regard.179 
(b) Human rights implications 
It is worth noting that the AoA does contain provisions that could protect particular 
countries or certain groups of people from the harmful effects of trade liberalisation 
and therefore facilitate a fairer trading system that is consistent with human 
rights.180 These include non-trade concerns (such as food security, rural 
development, rural livelihoods and protection of the environment), Special and 
Differential Treatment (designed to give developing countries greater flexibility in 
the implementation of WTO agreements),181 and the Special Safeguard (provided to 
countries that underwent tariffication in order to provide temporary protection to 
farmers in the event of spontaneous fluctuations in imports or falls in world 
commodity prices). While these measures are, for the most part, undefined and 
underutilised and implemented in a manner that does not ensure the protection of 
human rights, it can be argued that they nevertheless proffer an opportunity 
through which WTO Member States can, to some degree, fulfil their human rights 
obligations. It is notable, however, that developed countries often frustrate the 
effective implementation of these measures by failing to honour Special and 
Differential Treatment commitments or through attempts to weaken such 
provisions in WTO agreements. 
 When examining the human rights implications of the AoA, it is important to 
consider the impact of other factors such as the International Monetary Fund (IMF) 
and World Bank policies and, bilateral and regional trade arrangements which are 
all part of a broader trade liberalization agenda. Since the 1980s, the IMF and World 
Bank have prescribed economic austerity measures (structural adjustment 
programmes) in the context of which many developing countries have been 
constrained to reduce most of their trade barriers.182  This has negatively impacted 
on the ability of these countries to maintain better border protective measures or to 
implement domestic price controls. It has also affected their ability to harness 
sufficient resources to provide subsidies to their farmers struggling under the 
burden of cheap imports.  In Ghana, for example, the removal of subsidies to small-
scale tomato, rice and poultry farmers in the context of IMF and World Bank 
                                               
179 Wouter and De Meester (fn 8 above) 93. 
180 See 3D Planting the Rights Seed: A human rights perspective on agriculture trade and the WTO, 
Thread Backgrounder No 1 (2005) 6. 
181 Thus, for instance, under art 15(2) of the AoA, LDCs are exempted from domestic support 
reduction commitments for low-income farmers in order to encourage rural development. 
182 The ESCR Committee has taken a dim view of the human rights implications of IMF and World 
Bank structural adjustment policies. For example, in 2000, it stated that “some aspects of structural 
adjustment programmes and economic liberalization policies introduced by the Government of 
Egypt, in concert with international financial institutions, have impeded the implementation of the 
Covenant’s provisions, particularly with regard to the most vulnerable groups of Egyptian society”. 
See CESCR Concluding Observations: Egypt, Doc.E/C.12/1/Add.44 (2000). 
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prescribed liberalization programmes, led to an influx of cheap imports of these 
products from the US, Europe and Asia, which local consumers opted for to the 
detriment of the local farmers whose competitiveness had been significantly 
reduced by the lack of subsidies.183 
 This situation does not apply to the developed countries who have not been 
subjected to IMF and World Bank trade liberalisation measures requiring the 
removal of trade barriers and who have sufficient financial resources to provide 
subsidies to their farmers. 
 From a human rights perspective, however, the AoA has a number of defects. 
First, its export-oriented trade liberalisation approach focuses more on increasing 
international trade rather than on improving the livelihoods of those that are 
engaged in agricultural production.184 Second, it fails to deal with the problem of 
dominance of TNCs in the food production sector and the dumping of cheap produce 
to the detriment of the livelihoods of small-scale farmers who are driven out of 
business and impoverished as a consequence.185 This underscores the need for WTO 
Members to regulate TNCs more effectively.186 Third, the AoA has locked developing 
countries into an unfair trading system which significantly diminishes their ability 
to adopt domestic trade policies that are consistent with human rights.187 All of 
these issues affect many internationally-recognised human rights, such as the rights 
to life, to an adequate standard of living (including the right to food), to health, to 
work and to education.  
(c) The AoA and the Right to Food  
The right to food is enshrined in several international human rights and other 
instruments.188 The right is dealt with comprehensively in the ICESCR. Under article 
11(1) of this treaty, States Parties recognise “the right of everyone to an adequate 
standard of living for himself and his family, including adequate food, clothing and 
housing, and to the continuous improvement of living conditions”. In terms of article 
                                               
183 See 3D Integrating Human Rights into the Future of Agriculture, Report of a Workshop for human 
rights advocates on how to work to ensure that global agricultural policies are equitable and human 
rights consistent, Geneva, November 2004 available at http://www.3dthree.org/pdf_3D/ 
3DAg+HRenglish-couleur.pdf  (access confirmed: 30 January 2007). 
184 It should be noted in this regard that according to the WTO Agreement, the organisation’s aims 
are to raise living standards, ensure full employment and increase income. See 3D (fn 183 above) 8. 
185 3D (fn 183 above) 8.  
186 Failure to do so in circumstances where the activities of TNCs violate human rights might result in 
the state concerned incurring liability for the violations. See Social and Economic Rights Action Centre 
(SERAC) and Another v Nigeria (2001) AHRLR 60 (ACHPR 2001). 
187 It is notable that the obligation to cooperate internationally for the full realisation of human rights 
as set out in core human rights instruments implies that states have a duty to ensure that practices 
within their jurisdiction do not hamper other states’ attempts to effectively implement their human 
rights obligations.  See CESCR General Comment No 3: The Nature of States Parties Obligations (1990).  
188 For example, UDHR, article 25; ICESCR, article 11(1) and (2); CRC, article 24(2)(c); Geneva 
Convention IV, article 89; Protocol II, article 14.  
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11(2), States Parties recognise the need for immediate and urgent measures to 
ensure the “fundamental right to freedom from hunger and malnutrition”.  
 The ESCR Committee has defined the normative content of the right to adequate 
food in the following terms: 
The right to adequate food is realised when every man, woman and child, alone or in 
community with others, have physical and economic access at all times to adequate 
food or means of its procurement…. The core content of the right to adequate food 
implies the availability of food in quantity and quality sufficient to satisfy the dietary 
needs of individuals, free from adverse substances, and acceptable within a given 
culture; [and] the accessibility of such food in ways that are sustainable and that do 
not interfere with the enjoyment of other human rights.189  
 
In this context, availability refers to the possibilities either for feeding oneself 
directly from productive land or other natural resources, or for properly functioning 
distribution, processing and market systems that can move food from the place of 
production to the place of consumption in accordance with demand. The principle of 
accessibility encompasses both economic and physical accessibility. Economic 
accessibility implies that personal and household expenditure associated with the 
acquisition of food for an adequate diet should be at a level such that the fulfilment 
of other basic needs are not threatened or compromised. Physical accessibility 
implies that adequate food must be accessible to everyone, especially persons 
belonging to physically vulnerable groups.190 
 The right to food, like other human rights, imposes three types of obligations on 
States Parties to treaties enshrining the right: the obligations to respect, to protect 
and to fulfil. The obligation to respect existing access to adequate food requires 
States Parties not to take any measures that could hinder such access. The 
obligation to protect requires the State to take measures to ensure that third parties 
do not deprive individuals of their access to adequate food. In the SERAC case, the 
African Commission held that the right to food obliges states to protect and improve 
existing food sources and to ensure access to adequate food for all citizens.191 As a 
minimum, the right to food requires that states must refrain from destroying or 
contaminating food sources or preventing people’s efforts to feed themselves. The 
Commission concluded that by allowing private companies to destroy food sources, 
the Nigerian government had not fulfilled its obligations under the ACHPR and 
international human rights instruments and was therefore in violation of the Ogoni 
people’s right to food.192 This decision has significant implications for the regulation, 
                                               
189 CESCR General Comment No. 12: The Right to Adequate Food (Art 11), Doc.E/C.12/1999/5 (1999), 
para 3. 
190 These include infants and young children, elderly people, the physically disabled, and the 
terminally ill. 
191 See fn 186 above. 
192 See also Commission Nationale des Droits de l’Homme et des Libertes v Chad (2000) AHRLR 66 
(ACHPR 1995) where the African Commission found that the obligation in Article 1 of the ACHPR to 
“undertake … measures to give effect” to the rights in the ACHPR entails that if a state neglects to 
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by African states, of the activities of TNCs that may pose a threat to the livelihoods of 
their citizens and therefore also has implications for these States’ commitments 
under the AoA. 
 The obligation to fulfil human rights requires the State to proactively undertake 
activities calculated to enhance people’s access to and utilization of resources and 
means to ensure their livelihood, including food security and to provide the right 
directly to individuals or groups that are unable, for reasons beyond their control, to 
enjoy the right to adequate food. Where a State fails to ensure the satisfaction of, at 
least, the minimum essential level required to be free from hunger, it would be in 
violation of the right to adequate food. It should be noted that violations of the right 
to food can occur through the direct action of the State or other entities 
insufficiently regulated by the State.193 
 It is important to note that there are many dimensions to the right to food and its 
full realisation depends on a variety of factors, such as access to productive 
resources and paid employment. The right is also linked to other human rights, 
including the right to health, property rights (especially land rights), labour rights, 
access to justice and the right to information and education.194 
(d) Free trade and the Right to Food  
As in the case of most WTO agreements, the AoA is premised on free trade or trade 
liberalization. Proponents of trade liberalization argue that trade barriers are a 
costly and ineffective way of enhancing food security and development in poor 
countries.195   
 Conversely, opponents of free trade maintain that the free trade agenda fails to 
account sufficiently for the inequitable power relations between developed and 
developing countries that characterise the multilateral trade negotiation process. In 
their estimation, trade liberalisation jeopardises food security because it benefits 
only the larger and export-oriented farmers and marginalises small farmers and 
ultimately creates unemployment and poverty. They further contend that 
agricultural imports from developed countries expose food consumers to price 
shocks and small producers to risks and disincentives.  
                                                                                                                                            
ensure the rights in the Charter this would constitute a violation even if the state or its agents are not 
the immediate cause of the violation.  
193 See the Commission Nationale des Droits de l’Homme et des Libertes case (fn 193 above) and the 
SERAC case (fn 186 above). 
194 Vidar M “The Interrelationships between the Right to Food and Other Human Rights” in Eide and 
Kracht (fn 136 above). See also the SERAC case (fn 186 above), where the African Commission 
observed that the right to food is inseparably linked to human dignity and is as such essential for the 
enjoyment and fulfilment of such other rights as health, education, work and political participation.  
195 FAO The State of Food and Agriculture 2005 (2005) 3. According to the Food and Agriculture 
Organization (FAO), “multilateral trade offers opportunities for the poor and food-insecure by acting 
as a catalyst for change and by promoting conditions in which the food-insecure are able to raise 
their incomes and live longer, healthier and more productive lives” (at 6). 
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 While agricultural trade liberalization can create export opportunities in 
agricultural exporting countries and promote growth and development, it may also 
have adverse implications especially for small scale farmers and for food security. 
As the OHCHR has observed: 
Small farmers might not have the capacity to grow sufficient export crops and might 
even experience greater competition for resources, including land, thus 
marginalizing them from the potential benefits of trade. Similarly, greater export 
opportunities might lead to reallocation of land and other resources away from 
domestic food production, with possible adverse consequences for household food 
security.196 
 
It is notable that while the FAO which has highlighted the benefits of trade 
liberalisation it has also acknowledged that trade liberalization can have adverse 
effects: 
Opening national agricultural markets to international competition – especially 
from subsidized competitors – before basic market institutions and infrastructure 
are in place can undermine the agriculture sector, with long-term negative 
consequences for poverty and food security.197 
 
Illustratively, a 1999 study by the FAO evaluating the impact of the AoA on 
agricultural trade and food security in developing countries noted that while 
asparagus was the most dynamic export crop in Peru in the 1990s, the producers 
were mainly large scale farmers, not poor farmers.198 It concluded that the poor 
were likely to be the most adversely affected by open trade policies.199 In similar 
vein, the liberalization of maize in Zambia caused the producer price to fall and the 
consumer price to increase. As a consequence, there was a 20 per cent drop in maize 
consumption and an attendant increase in malnutrition and mortality. Owing to 
increased levels of poverty, health indictors declined and many families were unable 
to send their children to school.200 
 Thus, in order to minimize the adverse effects of trade liberalization, 
governments need to implement policies that complement trade reforms and enable 
the poor to take advantage of trade-related economic opportunities, while 
establishing safety nets to protect vulnerable members of society.201 As the OHCHR 
has observed, without the introduction of appropriate safeguards and transitional 
measures, trade rules could have adverse effects on the right to food, the rights of 
workers and other rights of small-scale farmers and the rural poor.202 However, it is 
                                               
196 OHCHR (fn 95 above) 2. See also FAO Agriculture, Trade and Food Security: Issues and Options in 
the WTO Negotiations from the Perspective of Developing Countries Vol II (2000). 
197 FAO WTO Agreement on Agriculture: The Implementation Experience – Developing Country Case 
Studies (2003) 6. 
198 Ibid.  
199 Ibid. 
200 3D (fn 183 above). 
201 See FAO Agriculture Trade and Poverty – Can Trade Work for the Poor (2005) 6. 
202 OHCHR (fn 95 above) 2. 
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difficult to see how developing countries would manage this, especially in the 
present international trade climate of distorted commodity markets and in which 
some developed countries retain import barriers, export subsidies and domestic 
support contrary to the spirit of the AoA. As stated above, the right to food includes 
both food security and the provision of employment opportunities. In the 
developing countries, the agricultural sector is not only the source of most of the 
food consumed, it is also the major source of employment. 
 While States are ultimately responsible for the realisation of the right to food in 
relation to persons under their jurisdiction, the ESCR Committee has emphasised 
the importance of international assistance and cooperation, especially “economic 
and technical”.203 The implications of this are, inter alia, that States Parties should 
respect the enjoyment of the right to food in other countries, protect that right, 
facilitate access to food and provide the necessary aid when required; and ensure, in 
relevant international agreements, that the right to food is given due attention. 
 
5  CONCLUSION 
Since its establishment just over a decade ago, the WTO has become one of the most 
influential international organisations. Its key purpose is to liberalize trade with the 
ultimate aim of promoting growth and economic development and raising living 
standards. In recent years, however, the organization’s trade liberalization agenda 
and its perceived lack of accountability and transparency have attracted intense 
criticism.  
 While it is generally accepted that trade has an important role to play in 
improving livelihoods, studies indicate that trade liberalization has not necessarily 
achieved this result for many of the WTO Members. Critics assert that the WTO 
agreements, most of which are based on the free trade ideal, ignore the unequal 
power relations inherent in negotiations between the developed and developing 
countries and that they pose a threat to the very livelihoods that the organization 
ostensibly seeks to improve as well as to human rights. While these agreements 
contain certain flexibilities that would, if effectively utilised, contribute to the 
realisation of human rights, these flexibilities have been rendered ineffective by 
developed countries through measures such as the adoption of TRIPS-plus rules in 
FTAs and the exertion of unilateral economic pressure. Consequently, it is 
contended that trade liberalization has in fact created an unjust global trading order 
in which rich countries are benefiting at the expense of poor countries and the latter 
are increasingly placed in a situation where they are unable to give full effect to 
their commitments under international human rights treaties. 
 This situation underscores the need for the WTO and its Members to adopt a 
human rights approach in the design, implementation and assessment of trade 
                                               
203 See General Comment No 3 (fn 189 above) para 13. 
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liberalization policies. This will afford those affected by trade policy the opportunity 
to participate more effectively in the formulation of trade policies to ensure that 
such policies are more transparent, accountable and responsive to the needs of the 
people they are designed to serve. Further, flexible or innovative interpretation of 
the WTO rules by the organisation’s dispute settlement mechanism will arguably 
also enhance the prospects for the protection and promotion of human rights, albeit 
indirectly and in a limited manner. 
 Finally, it is important to emphasise that states bear the primary responsibility 
for ensuring the protection and promotion of the rights to health and adequate food. 
Although the TRIPS and AoA place limitations on how WTO Members regulate trade, 
national governments retain a range of options that they can pursue to ensure the 
realisation of the rights to health and food in an era of trade liberalization. However, 
the flexibilities proffered by these agreements need to be utilised to the fullest 
extent possible if they are to be effective from a human rights perspective.  Further, 
WTO rules must not reduce or undermine the ability of Member States to meet their 
human rights obligations to persons within their territories and subject to their 
jurisdiction. As the primary bearers of obligations under international human rights 
law, States must also carry out human rights impact assessments before 
undertaking new commitments under bilateral and multilateral trade agreements. 
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